Company

Stuart Therapeutics, Inc.

Stuart Therapeutics develops treatments for chronic eye diseases using its PolyCol TM platform.

About

Founded in 2017 and based in Stuart, US, Stuart Therapeutics develops ocular therapies using its PolyCol TM platform, which is designed to repair damaged collagen in eye tissue. Its programs target conditions including dry eye disease, glaucoma, and dry age-related macular degeneration. The company raised USD 11.00 mn in Series A funding on March 19, 2021.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in